Recently, Spaan et al. explored the effect of DAAs therapy on NK cells; they found that DAAs therapy increased the percentage of CD3+CD56dim NK cells, downregulated surface NKp30, NKp46, and NKG2A expression on NK cells to a phenotype resembling healthy controls, and decreased NK cell-related cytokines (IL-12, IL-18) and TRAIL expression of CHC patients during DAAs treatment [26]. This evidence concerns the gene NCR1 and cryohydrocytosis.